+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Periodontal Therapeutics Market Report and Forecast 2023-2031

  • PDF Icon


  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797830
The global periodontal therapeutics market size attained a value of USD 2.8 billion in 2022. The market is anticipated to grow at a CAGR of 8.7% during the forecast period of 2023-2031 to attain a value of USD 5.98 billion by 2031.

Periodontal Therapeutics Market: Introduction

Periodontal therapeutics refers to the treatment options available for managing periodontal diseases, which are infections of the structures around the teeth, including the gums, periodontal ligament, and alveolar bone. The most common form of periodontal disease is gingivitis, which affects the gums, but the infection can progress to more serious conditions like periodontitis, which can lead to tooth loss.

Periodontal therapeutics consists of both non-surgical and surgical treatment methods:
  • Non-surgical treatments include professional dental cleaning, scaling, and root planning (deep cleaning), and the use of medications. Medications may include antimicrobial mouth rinses, antiseptic chips, antibiotic gels, enzyme suppressants, and oral antibiotics
  • Surgical treatments include flap surgery (pocket reduction surgery), soft tissue grafts, bone grafting, guided tissue regeneration, and tissue-stimulating proteins
The primary aim of periodontal therapeutics is to control the infection and prevent further progression of the disease. The approach taken will depend on the severity of the disease and the response to initial treatments.

Benefits of periodontal therapeutics include:

  • Improved Oral Health: Effective treatment can help to stop the progression of periodontal disease, preventing tooth loss and protecting overall oral health.
  • Reduced Risk of Systemic Diseases: There is increasing evidence linking periodontal disease with systemic conditions such as cardiovascular disease, diabetes, and respiratory diseases. Therefore, managing periodontal disease can also help to reduce the risk of these conditions.
  • Improved Quality of Life: By treating the symptoms of periodontal disease, such as swollen, bleeding gums, persistent bad breath, and loose teeth, periodontal therapeutics can improve the quality of life and boost self-confidence.
  • Prevention of Infection Spread: By controlling the oral infection, periodontal therapeutics prevent the spread of infection to other parts of the body.
In conclusion, periodontal therapeutics plays a crucial role in managing periodontal diseases, improving oral health, and potentially reducing the risk of associated systemic diseases.

Periodontal Epidemiology
The epidemiology of periodontal disease can be characterized by factors such as prevalence, age, gender, and lifestyle habits:
  • Prevalence: Periodontal disease is one of the most prevalent oral diseases worldwide, affecting a significant portion of the global population. The World Health Organization estimates that severe periodontal disease, which may result in tooth loss, is found in 10-15% of most populations globally. However, milder forms of the disease, such as gingivitis, are even more common
  • Age: The prevalence of periodontal disease generally increases with age. While gingivitis is common in children and adolescents, more severe forms of periodontal disease, such as periodontitis, are more common in adults. The Centres for Disease Control and Prevention (CDC) estimates that over 70% of Americans 65 and older have periodontitis
  • Gender: Some studies suggest that men are more likely to have periodontal disease than women. This could be due to differences in oral health practices, risk behaviours, or hormonal fluctuations. However, more research is needed in this area to draw definitive conclusions
  • Lifestyle Habits: Lifestyle factors play a significant role in the development and progression of periodontal disease. Smoking is a major risk factor and is associated with both the onset and severity of the disease. Poor oral hygiene practices, such as infrequent brushing and flossing, also increase the risk. Other factors include a diet low in essential nutrients, stress, and certain medical conditions such as diabetes
Geographically, the prevalence of periodontal disease varies globally, with certain regions showing higher rates due to factors like access to dental care, socioeconomic status, and cultural practices.

Understanding the epidemiology of periodontal disease can help healthcare providers and policymakers develop strategies for prevention and treatment, with the goal of reducing the burden of this widespread oral health problem.

Periodontal Therapeutics Market Segmentations

The market can be categorised into product, treatment type, disease type, end user, and region.

Periodontal Therapeutics Market Breakup by Product

  • Systemic Antibiotics
  • Local Antibiotics

Periodontal Therapeutics Market Breakup by Treatment type

  • Non-Surgical Treatment
  • Surgical Treatment

Periodontal Therapeutics Market Breakup by Disease type

  • Gingivitis
  • Chronic Periodontal Disease
  • Aggressive Periodontal Disease
  • Others

Periodontal Therapeutics Market Breakup by End user

  • Hospitals
  • Dental Clinics
  • Dental Academics and Research Institutes
  • Others

Periodontal Therapeutics Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Periodontal Therapeutics Market Scenario

  • The global periodontal therapeutics market is expected to grow in the coming years due to several contributing factors. The market's growth is primarily driven by the increasing prevalence of periodontal diseases, growing awareness about oral health, advances in therapeutic options, and a rise in risk factors such as diabetes and lifestyle habits like smoking
  • Periodontal diseases, including gingivitis and periodontitis, are among the most common health conditions worldwide. This high prevalence, coupled with increasing awareness of the importance of oral hygiene and regular dental check-ups, is contributing to the growing demand for periodontal therapeutics. Moreover, as the global population ages, the incidence of periodontal disease is expected to increase further, driving the need for effective treatment options
  • The market comprises various products, including systemic antibiotics, local antibiotic therapy, mouth rinses, and surgical instruments, among others. The development and approval of novel therapeutic products also propel the market's growth. For instance, the introduction of locally applied antimicrobials and host modulation therapy offers new treatment avenues for periodontal diseases
  • Geographically, North America holds a significant share of the global periodontal therapeutics market, attributed to the high prevalence of periodontal diseases, well-established healthcare infrastructure, and heightened awareness about oral health. However, the Asia-Pacific market is expected to witness the fastest growth due to improving healthcare facilities, increasing disposable income, and a growing patient population
  • Despite the promising growth, the market faces some challenges. The high cost of periodontal treatment, lack of awareness in certain regions, and underdiagnosis of periodontal disease can potentially limit the market's growth
In conclusion, the global periodontal therapeutics market is set to witness robust growth in the coming years, thanks to increasing disease prevalence, growing awareness, and the introduction of advanced treatment options. However, addressing barriers such as cost and awareness is vital to ensure the market reaches its full potential.

Key Players in the Global Periodontal Therapeutics Market

The report gives an in-depth analysis of the key players involved in the periodontal therapeutics market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • 3M Company
  • Den-Mat Holdings, LLC
  • Dexcel Pharma
  • Kaken Pharmaceutical Co., Ltd
  • Bausch Health Companies Inc
  • Colgate-Palmolive Company (India) Limited
  • Mylan N.V
  • Pfizer Inc
  • Noveome Biotherapeutics, Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Periodontal Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Periodontal Disease Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Periodontal Disease Epidemiology (2016-2031)
5.3 Europe Periodontal Disease Epidemiology (2016-2031)
5.4 Asia-Pacific Periodontal Disease Epidemiology (2016-2031)
5.5 Latin America Periodontal Disease Epidemiology (2016-2031)
5.6 Middle East & Africa Periodontal Disease Epidemiology (2016-2031)
6 Global Periodontal Therapeutics Market Overview
6.1 Global Periodontal Therapeutics Market Historical Value (2016-2022)
6.2 Global Periodontal Therapeutics Market Forecast Value (2023-2031)
7 Global Periodontal Therapeutics Market Landscape
7.1 Periodontal Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Periodontal Therapeutics: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by Treatment
7.2.3 Analysis by Disease Type
7.2.4 Analysis by End User
8 Periodontal Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Periodontal Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Periodontal Therapeutics Market Segmentation
11.1 Global Periodontal Therapeutics Market by Product
11.1.1 Market Overview
11.1.2 Systemic Antibiotics
11.1.3 Local Antibiotics
11.2 Global Periodontal Therapeutics Market by Treatment Type
11.2.1 Market Overview
11.2.2 Non-Surgical Treatment
11.2.3 Surgical Treatment
11.3 Global Periodontal Therapeutics Market by Disease Type
11.3.1 Market Overview
11.3.2 Gingivitis
11.3.3 Chronic Periodontal Disease
11.3.4 Aggressive Periodontal Disease
11.3.5 Others
11.4 Global Periodontal Therapeutics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Dental Clinics
11.4.4 Dental Academics and Research Institutes
11.4.5 Others
11.5 Global Periodontal Therapeutics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Periodontal Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Periodontal Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Periodontal Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Periodontal Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Periodontal Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 3M Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Den-Mat Holdings, LLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Dexcel Pharma
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Kaken Pharmaceutical Co., Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Bausch Health Companies Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Colgate-Palmolive Company (India) Limited
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Mylan N.V.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Pfizer Inc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Noveome Biotherapeutics, Inc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Periodontal Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • 3M Company
  • Den-Mat Holdings, LLC
  • Dexcel Pharma
  • Kaken Pharmaceutical Co. Ltd.
  • Bausch Health Companies Inc.
  • Colgate-Palmolive Company (India) Limited
  • Mylan N.V.
  • Wockhardt
  • Pfizer Inc
  • Noveome Biotherapeutics, Inc



Table Information